malecare - malecare.org

On the Horizon – Denosumab, An alternative To Zometa To Protect Bones While Treating Advanced Prostate Cancer

Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events Amgen (NASDAQ: AMGN) has announced positive results from a Phase III head-to-head trial evaluating denosumab administered subcutaneously, versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion. Currently Zometa is the FDA approved treatment for bone [...]

By Malecare|2017-10-19T10:54:43-04:00August 9th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Metastases, On The Horizon, Uncategorized, Understanding APC|0 Comments

How a Prostate Cancer Recurrence Is Currently Dealt With – Salvage Methods For Recurrent Prostate Cancer After Failure Of PrimaryRadiotherapy

The authors of a recent study from the Duke Prostate Center and Division of Urology, Department of Surgery, Duke University Medical Center, Durham, N.C. and the Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan reviewed the current salvage methods for treating recurrent local recurrent prostate cancer after primary radiotherapy (RT). They used a [...]

By Malecare|2017-10-19T10:54:43-04:00August 7th, 2009|Advanced Prostate Cancer, Drugs & Treatments, General Information, Technology, Uncategorized, Understanding APC|1 Comment

Combined Androgen Blockade (ADT2) with Bicalutamide (Casodex) For Advanced Prostate Cancer Provides Increased Survival Time

One of the first treatments used when diagnosed with advanced or recurrent prostate cancer is hormone therapy. Hormone therapy (androgen blockade) is a systematic treatment, or it treats the cancer through the entire body. Prostate cancer that is believed to be in the gland is treated with a localized, focused treatment of the actual gland [...]

By Malecare|2017-10-19T10:54:44-04:00August 5th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

On the Horizon – Positive Efficacy Data From Phase I – II Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

Medivation, Inc. (MDVN) announced that its on-going clinical trial (phase I & II) of MDV3100 in castrate resistant prostate cancer has demonstrated both efficacy and safety in its current trials. The drug under study, MDV3100, is novel androgen receptor antagonist. This trial tracked 114 prostate cancer survivors who are hormone resistant (CRPC) for 12 weeks [...]

By Malecare|2017-10-19T10:54:44-04:00August 4th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, On The Horizon, Technology, Uncategorized|0 Comments

Cancer Survivors Face Psychological Difficulties, Even After Treatment Ends

We all do know that being a cancer survivor means that you are at an increased risk to suffer serious psychological distress such as anxiety and depression The surprise is that this increased susceptibility can extend even a decade after the treatment ends. Survivors who are diagnosed in their younger years, unmarried, had less than [...]

By Malecare|2017-10-19T10:54:44-04:00August 3rd, 2009|Advanced Prostate Cancer, Advocacy, General Information, How We Live, Uncategorized, Understanding APC|0 Comments